Related Experiment Video
Updated: Apr 22, 2026

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4
Published on: August 21, 2017
[Diagnosis and treatment of neuromyelitis optica]
Helle Hvilsted Nielsen1, Mads Ravnborg, Zsolt Illes
1Neurologisk Afdeling, Odense Universitetshospital, Sdr. Boulevard 29, 5000 Odense C. hhnielsen@health.sdu.dk.
Abstract:
Neuromyelitis optica (NMO) is an inflammatory demyelinating disease characterized by antibodies against aquaporin-4 in up to 80% of the cases and even less in the NMO spectrum disorders, which may be difficult to distinguish from early multiple sclerosis. While immunosuppressive therapy should be introduced in definite NMO, treatment strategies of NMO spectrum disorders are less clearly defined. Here, we review the current guidelines for treatment of NMO and NMO spectrum disorders in the light of two cases, and suggest a practical approach to the management of these disorders.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Myasthenia Gravis: Diagnostic Tests
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Multiple Sclerosis l: Introduction
Angle Closure Glaucoma: Treatment
Nephrotic Syndrome II : Assessment and Medical Management

